Immunogenicity and protective efficacy of  serovar Pullorum pathogenicity island 2 mutant as a live attenuated vaccine candidate by unknown
RESEARCH ARTICLE Open Access
Immunogenicity and protective efficacy of
Salmonella enterica serovar Pullorum
pathogenicity island 2 mutant as a live
attenuated vaccine candidate
Junlei Yin, Zhao Cheng, Lijuan Xu, Qiuchun Li, Shizhong Geng, Zhiming Pan and Xinan Jiao*
Abstract
Background: Salmonella enterica serovar Pullorum (S. Pullorum) causes Pullorum disease (PD), a severe systemic
disease of poultry and results in considerable economic losses in developing countries. In order to develop a safe
and immunogenic vaccine, the immunogenicity and protective efficacy of S06004ΔSPI2, a Salmonella pathogenicity
island 2 (SPI2) deleted mutant of S. Pullorum was evaluated in 2-day old chickens.
Results: Single intramuscular vaccination with S06004ΔSPI2 (2 × 107 CFU) of chickens revealed no differences in
body weight or clinical symptoms compared to control group. S06004ΔSPI2 bacteria can colonize and persistent
in liver and spleen of vaccinated chickens approximately 14 days, and specific humoral and cellular immune
responses were significantly induced. Vaccination of chickens offered efficient protection against S. Pullorum
strain S06004 and S. Gallinarum strain SG9 challenge, respectively, at 10 days post vaccination (dpv) based on
mortality and clinical symptoms compared to control group.
Conclusions: These findings suggest that S06004ΔSPI2 appears to be a highly immunogenic and efficient live
attenuated vaccine candidate.
Keywords: Salmonella enterica serovar Pullorum, Pullorum disease, Salmonella pathogenicity island 2, live
attenuated vaccine
Background
Salmonella enterica serovar Pullorum (S. Pullorum) is
the causative agent of Pullorum disease (PD), an acute
systemic disease that results in high morbidity and mor-
tality in young chicks and a loss of weight, decreased fer-
tility and hatchability, lesions, diarrhea and abnormalities
of the reproductive tract in infected adults, it can be trans-
mitted vertically to chicks through eggs [1]. This disease
remains a big threat of restricting the growth of the
poultry industry in developing countries [2]. As a close
relative of S. Pullorum, Salmonella enterica serovar Galli-
narum (S. Gallinarum) causes Fowl typhoid (FT), a severe
systemic disease with significant morbidity and mortality
in poultry in many countries [2–5].
Vaccination is an effective strategy for the control of
Salmonella infections, both humoral and cellular im-
munity are required for ideal Salmonella vaccines [6].
Live vaccines offer greater protection than killed vac-
cines because higher cellular immune response could be
induced, it is important for clearance of Salmonella in-
fections [6].
As an indispensable virulence determinant associated
with the systemic infections, Salmonella pathogenicity is-
land 2 (SPI2) can encode type III secretion system 2
(T3SS2), which is induced after invasion, and the T3SS2 se-
creted effectors are essential for Salmonella to survive and
replicate inside various cell types [7, 8]. There are some pa-
pers on the vaccine potential of S. Enteritidis, S. Typhimur-
ium and S. Typhi mutants with deletion of SPI2 or other
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key genes located within the pathogenicity island display
decreased virulence in poultry, pigs, cattle, mice, and
humans [9–14]. Therefore, in order to determine whether
the SPI2 mutant strain of S. Pullorum has the vaccine po-
tential, we evaluated the immunogenicity and protective ef-
ficacy of S06004ΔSPI2 in susceptible HY-line white
chickens. Our results showed that intramuscular vaccin-
ation with S06004ΔSPI2 provides efficient protection
against challenges with S. Pullorum and S. Gallinarum.
Methods
Experimental animals
The animal experiments were conducted with the ap-
proval of the Animal Care and Ethics Committee of
Yangzhou University. HY-line white chicken eggs were
hatched and the chickens were detected for freedom
from any clinical signs of enteric disease and negative
for Salmonella. Two-day old chickens were used in this
study and given antibiotic–free food and water through-
out the experimental period.
Bacterial strains
S. Pullorum S06004 (accession No. CP006575.1), a nali-
dixic acid-resistant (Nalr) clinical isolate obtained from
chickens with Pullorum disease in the Jiangsu Province
of China in 2006 [15], and the virulent wild type S. Galli-
narum strain SG9 (Nalr), supplied by Dr. Barrow [16],
were used as challenge strains. S06004ΔSPI2 (Nalr, the
whole SPI2 (~40 kb) deleted mutant of S. Pullorum
S06004), constructed using the one-step inactivation
method described by Datsenko and Wanner [17, 18],
was used as the vaccine candidate for this study. Bacter-
ial strains were stored as frozen cultures in Luria-Bertani
(LB) broth with 20 % glycerol at −70 °C before use. LB
broth, LB solid (15 g/L agar) and XLT4 (Difco) agar were
used for culturing bacteria at 37 °C. The media were
supplemented with Nal (40 μg/ml) as required.
Bacterial inoculation in chickens
One hundred 2-day old chickens were randomly
assigned to 2 groups: vaccinated group (n = 45) and con-
trol group (n = 55). The vaccinated group was intramus-
cularly immunized with 2 × 107 CFU S06004ΔSPI2 in
100 μl phosphate buffered saline (PBS), while control
group was unimmunized and only received equal
amounts PBS.
Changes of body weight and clinical symptoms after
vaccination
Body weights of these chickens were measured at 5, 12
and 19 days post vaccination (dpv), and they were moni-
tored for 19 days for clinical signs of disease, which in-
cluded anorexia, diarrhea and depression, etc.
Bacterial persistence and clearance from internal organs
Liver and spleen samples of five chickens from each group
were aseptically collected at 5, 7, 10, 14 and 21 dpv for
bacterial recovery. Then they were weighed and sus-
pended in 1 ml PBS and homogenized individually. Ho-
mogenates (100 μl) of different dilutions were inoculated
on XLT4 agar (containing 40 μg/ml Nal) for enumeration
and incubated for 20 h at 37 °C. The bacterial number in
the sample was counted and expressed as log10 CFU/g,
negative samples were indicated as 0 CFU/g.
Immune responses induced by the vaccine strain
Humoral immune responses were evaluated through de-
termination of Specific antibody IgG levels by Enzyme-
linked immunosorbent assay (ELISA), using heat-killed
whole S. Pullorum bacteria as coating antigen as previ-
ously described [19]. Serum samples were collected from
five chickens of each group at 3, 7, 14 and 21 dpv, and
diluted 1:50 to be used as the primary antibody. The
secondary antibody was Horseradish peroxidase (HRP)-
conjugated rabbit anti-chicken IgG (1:10,000 dilution).
The bound HRP activity was determined using o-
phenylenediamine dihydrochloride (Sigma), and the OD492
was determined with an ELISA reader after the reactions
were stopped by 2 M H2SO4.
Cellular immune responses were evaluated by the per-
ipheral mononuclear cell proliferation assay as previ-
ously described [20, 21]. Soluble antigen was prepared
from the wild type S. Pullorum strain S06004. Peripheral
lymphocytes were separated from blood of five birds per
group using the Histopaque®-1077 (Sigma) at 7, 14 and
21 dpv. After trypan blue dye exclusion testing, a viable
mononuclear cell suspension (100 μl) at 1 × 106 CFU/ml
in RPMI-1640 medium with 10 % fetal calf serum,
2 mM L-glutamine, 50 U/ml of penicillin and 50 μg/ml
of streptomycin was incubated in triplicate in 96-well
tissue culture plates with 50 μl of medium alone or
medium containing 4 μg/ml of soluble antigen at 41 °C
(in a humidified 5 % CO2 atmosphere for 48 h). The
proliferation of stimulated lymphocytes was measured
using adenosine triphosphate (ATP) bioluminescence
with the ViaLight® Plus Kit (Lonza Rockland, ME, USA).
The blastogenic response against soluble antigen was
Table 1 Mean body weights of chickens after vaccination. The
vaccinated group was intramuscularly immunized with 2 × 107 CFU
S06004ΔSPI2 in 2-day old chickens, and control group received
100 μl PBS
Group Mean body weight per chicken at dpv (g)
5 12 19
vaccinated 65.416 ± 0.418 113.878 ± 0.493 186.583 ± 0.716
Control 64.592 ± 0.782 114.618 ± 0.795 187.171 ± 0.385
There were no significant differences between groups at any time
point (P > 0.05)
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expressed as the mean stimulation index (SI) as previ-
ously described [20].
Evaluation of immune protection
Protective efficacy of S06004ΔSPI2 against challenges with
S. Pullorum and S. Gallinarum were assessed, based on
survival rates and clinical symptoms (including anorexia,
diarrhea, depression, high morbidity and mortality). At 10
dpv, twenty chickens from vaccinated group were ran-
domly divided into two groups of 10 animals (group A
and C), thirty chickens from control group were randomly
divided into three groups of 10 animals (group B, D
and E). Group A and B were challenged intramuscularly
with 2 × 109 CFU S06004 in 100 μl of PBS. Groups C
and D received equal amounts of SG9. Group E only
received 100 μl PBS. The surviving birds were counted
at 21 days post challenge, and clinical symptoms were
recorded every day from 1–35 dpv.
Statistical analysis
All data were expressed as mean ± standard error of the
mean (SEM) values unless otherwise specified and ana-
lyzed with GraphPad Prism. P values less than 0.05 were
considered significant when using one-way analysis of
variance (ANOVA).
Results
Changes of body weight and clinical symptoms after
vaccination
After vaccination with S06004ΔSPI2, the mean body
weight of each chicken in vaccinated group and control
group at 5, 12 and 19 dpv were shown in Table 1. No sig-
nificant differences and no clinical signs (anorexia, diarrhea
and depression) were observed between the two groups.
Bacterial persistence and clearance in internal organs
All liver and spleen samples of control group were nega-
tive for Salmonella recovery. As shown in Fig. 1, the
considerably decreased bacterial counts of vaccinated
group were continuously observed through to 21 dpv in
both liver and spleen, but S06004ΔSPI2 bacteria can
colonize and persistent in liver and spleen of vaccinated
chickens approximately 14 days. Only one spleen sample
was positive and no liver sample was positive at 21 dpv.
Humoral and cellular immune responses
Humoral immune responses were evaluated by measur-
ing specific serum IgG levels at 3, 7, 14 and 21 dpv using
ELISA. The mean OD492 values of vaccinated group were
0.221 ± 0.019, 0.484 ± 0.039, 0.678 ± 0.056 and 1.032 ±
0.064 at 3, 7, 14 and 21 dpv, respectively (Fig. 2). The
chickens in vaccinated group had significantly higher
serum IgG levels than those in control group at 7, 14
and 21 dpv. The considerably elevated serum IgG levels
of vaccinated group were continuously observed through
to 21 dpv.
Cellular immune responses were examined by the per-
ipheral mononuclear cell proliferation assay. The mean SI
values of vaccinated group were 3.124 ± 0.138, 3.495 ±
0.188 and 2.667 ± 0.189 at 7, 14 and 21 dpv, respectively
(Fig. 3). All tested chickens in vaccinated group revealed
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Fig. 1 Bacterial recovery from liver and spleen of the vaccinated chickens. The vaccinated group was intramuscularly immunized with 2 × 107 CFU
S06004ΔSPI2 in 2-day old chickens, and control group received 100 μl PBS. Values represent the mean ± SEM log10 CFU/g. All liver and spleen
samples of control group were negative


















Fig. 2 Determination of serum IgG levels. Vaccinated group and
control group refer to Fig. 1. Values represent the mean ± SEM.
*Significant difference compared to the control group, P < 0.05
Yin et al. BMC Veterinary Research  (2015) 11:162 Page 3 of 6
considerably elevated SI values compared to control
group, and the significantly elevated SI values was con-
tinuously observed at 14 dpv, but was reduced at 21 dpv.
Immune protection
The percent survival of chickens which had been vac-
cinated intramuscularly with S. Pullorum mutant
S06004ΔSPI2 followed by challenge with the parent S.
Pullorum strain S06004 or S. Gallinarum strain SG9 at
10 dpv was shown in Table 2. One immunized chicken
died, whereas nine chickens died in control group B
after challenged with S06004. Three immunized chickens
died, whereas all ten chickens died in control group D
after challenged with SG9. The clinical symptoms (high
morbidity and mortality, anorexia, diarrhea, depression) of
group A and C were slight and temporary after challenged
compared to group E, and the chickens had recovered by
3–7 days post challenge; but these clinical symptoms were
observed in group B and D. S06004ΔSPI2 conferred ef-
fective protection.
Discussion
In this work, we evaluated the immunogenicity and pro-
tective efficacy of a Salmonella pathogenicity island 2
(SPI2) deleted mutant of S. Pullorum (S06004ΔSPI2) to
serve as a live vaccine against PD and FT in susceptible
HY-line white chickens on the basis of changes of body
weight and clinical symptoms, bacterial persistence and
clearance, humoral and cellular immune responses, and
protective efficiency.
In order to evaluate the effects of S06004ΔSPI2 on
growth performance in chickens, we recorded the body
weight increases and observed the clinical symptoms
after intramuscular vaccination. Our results showed that
S06004ΔSPI2 has almost no side effects on growth per-
formance in chickens. T3SS2 encoded by SPI2 is essen-
tial for Salmonella colonization and persistence in host.
With the absence of a functional T3SS2, Salmonella is
cleared more rapidly than the parental wild type strain
from the host, and some studies have failed to isolate
SPI2 mutants from liver and spleen after oral inoculation
[5, 16, 22]. Here, our results showed that S06004ΔSPI2
can colonize and persist in liver and spleen of vaccinated
chickens approximately 14 days, this may be related to
the breed of chicken, the routes of vaccination and the
dose of inoculation.
Specific humoral and cellular immune responses in-
duced by the live attenuated vaccines of Salmonella are
crucial for the natural host [6]. To investigate the specific
humoral immune responses imparted by the candidate, we
examined the specific serum IgG antibody level by indirect
ELISA, there was a strong specific serum IgG level in vac-
cinated chickens, and the antibodies were detectable at 7
dpv. The vaccinated chickens showed significantly elevated
IgG levels compared to non-immunized chickens. S. Enter-
itidis SPI2 mutant can also induce significant increase of
antibodies in chickens [9]. Cellular immune responses play
a central role in protection against Salmonella challenge,
because Salmonella are facultative intracellular pathogens
[23]. We further evaluated the cellular immune responses
imparted by the candidate in chickens using the peripheral






















Fig. 3 Stimulation index (SI) of chicken lymphocyte samples
determined by peripheral lymphocyte proliferation assay using
soluble antigen. Vaccinated group and control group refer to Fig. 1.
Values represent the mean ± SEM. *Significant difference compared
to the control group, P < 0.05
Table 2 Protective efficacy of S06004ΔSPI2. Group A and C were intramuscularly immunized with 2 × 107 CFU S06004ΔSPI2 in
2-day old chickens, group B, D and E were nonimmunized. At 10 dpv, group A–D were challenged
Group Vaccination Number Challenge Survivors/Total Survival rate (%)
Strain Strain Route Dose (CFU)
A S06004△SPI2 10 S06004 intramuscularly 2 × 109 9/10 90*
B PBS 10 S06004 intramuscularly 2 × 109 1/10 10
C S06004△SPI2 10 SG9 intramuscularly 2 × 109 7/10 70*
D PBS 10 SG9 intramuscularly 2 × 109 0/10 0
E PBS 10 — — — 10/10 100
*P < 0.05 for comparison of group A with group B, and group C with group D
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significantly elevated cellular immune response was clearly
observed in chickens immunized with S06004ΔSPI2, but
the significantly elevated SI value was decreased at 21 dpv,
it is related to the restricted colonization of bacteria in in-
ternal organs [24, 25]. Taken together, the specific humoral
and cellular immune responses were clearly observed in
the vaccinated chickens in this study.
Several previous reports have shown that live attenu-
ated Salmonella vaccines can confer effective cross-
protection to different pathogenic Salmonella serovars
[26, 27]. Here, we evaluated the protective efficacy of the
candidate vaccine against challenge intramuscularly with
S. Pullorum and S. Gallinarum, respectively, based on
survival rates and clinical symptoms in HY-line white
chickens. The survival rates were 90 % and 70 % follow-
ing respective challenge with S. Pullorum and S. Galli-
narum in vaccinated chickens; but in the control groups,
the survival rates were 10 % and 0, respectively. The
light and temporary clinical symptoms of vaccinated
chickens (group A and C) had recovered by 3–7 days
post-challenge. Recently, our results also showed that
S06004ΔSPI2 can be used as a live attenuated oral vaccine
[28]. Overall, these results showed that the candidate vac-
cine S06004ΔSPI2 can afford effective protection for acute
systemic PD and FT infection.
Conclusions
Our present work demonstrated that the vaccination
of susceptible chickens with the candidate vaccine
S06004ΔSPI2 conferred development of acquired immun-
ity and efficient protection for the experimental systemic
PD and FT infection. Taken together, the SPI2 mutant
strain of S. Pullorum has the potential of being used as
a safe, novel, highly immunogenic vaccine against PD
and FT.
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